Group 1 - The core viewpoint of the articles emphasizes that 2025 was a year of rational value and long-termism for the biopharmaceutical industry, rather than a winter or bubble phase [1] - The company achieved significant milestones, including the successful listing on the Hong Kong Stock Exchange on December 30, 2025, becoming the largest biotech company by financing scale in the Hong Kong market that year [1] - The company established collaborations with major pharmaceutical firms such as Eli Lilly, Sihuan Pharmaceutical, and Fosun Pharma, and made progress in clinical and preclinical projects [1] Group 2 - In the AI pharmaceutical sector, AI has transitioned from being viewed as a "black box" to a foundational element, with more pharmaceutical companies adopting and deploying AI technologies [2] - The company has gained trust from the industry and partners through its benchmark capabilities in AI drug development and continuous output of preclinical candidates [2] - Looking ahead to 2026, the company aims to expand into broader life sciences areas and explore new molecular entities, including the establishment of an AI-driven automated peptide screening platform [2]

Core Insights - The collaboration in the AI pharmaceutical sector has significantly accelerated entering 2026, with notable partnerships being formed, including a recent agreement between Insilico Medicine and Kangzheng Pharmaceutical for AI-driven drug development [1][3]. Company Overview - Insilico Medicine, founded in 2014, is an AI-driven innovative pharmaceutical company that relocated from the U.S. to Hong Kong in 2019. It has developed over 20 clinical or IND assets through its generative AI platform, Pharma.AI [2]. - The company successfully went public on the Hong Kong Stock Exchange in December 2025, marking the largest biotech IPO in the Hong Kong market for that year [2]. Recent Collaborations - The recent partnership with Kangzheng Pharmaceutical is the fourth deal Insilico Medicine has secured in 2026, with total payments from previous collaborations amounting to $42 million, contributing to a cumulative total exceeding $1 billion across various therapeutic areas [3]. - Other collaborations include partnerships with Shiweya, Hengtai Biotech, and Qilu Pharmaceutical, focusing on oncology, central nervous system, and autoimmune diseases [3]. Industry Trends - The surge in collaborations indicates a shift from "proof of concept" to "commercial realization" in AI pharmaceuticals, with traditional pharmaceutical companies increasingly adopting AI technologies due to their efficiency and cost advantages [3][4]. - Insilico Medicine's AI platform significantly reduces the time required to identify clinical candidates from an average of 4.5 years to 12-18 months, while also decreasing the number of synthesized molecules and associated costs [4]. Cost Efficiency - Traditional drug development requires synthesizing hundreds to thousands of molecules, whereas Insilico Medicine only needs to synthesize dozens to a few hundred, reducing costs from over $10 million to approximately $2-3 million [4]. Industry Sentiment - A report cited by Guosheng Securities indicates that 85% of surveyed company leaders are increasing investments in AI, with 70% considering it a top priority. There is a notable shift towards collaboration or acquisition of external AI solutions rather than in-house development [4].

Group 1 - Multiple Hong Kong AI medical concept stocks showed active performance, with companies like Inspur Intelligent (03696.HK) rising by 7.59% to reach a new high since listing, and Yunzhisheng (09678.HK) increasing by over 6%, driven by positive business developments and long-term industry prospects [2] - Recent strategic collaborations among leading companies in the AI medical field are accelerating the commercialization of their technology platforms, with Inspur Intelligent partnering with Kangzhi Pharmaceutical for drug development in central nervous system and autoimmune diseases, potentially receiving tens of millions of Hong Kong dollars in research funding for each project [3] - Crystal Tech Holdings has also made significant moves, delivering an automated workstation for formula stability testing to BASF and announcing a long-term strategic partnership with Weisheng Pharmaceutical to integrate their AI+robotics drug development platform [3] Group 2 - AI technology is becoming a key solution to long-standing challenges in drug development, such as lengthy cycles, high costs, and high failure rates, by efficiently identifying targets and predicting molecular properties through deep learning [4] - Industry leaders, including NVIDIA's founder Jensen Huang, recognize that AI will have a profound impact on life sciences, indicating a potential revolution in drug development models [4] - Several domestic AI model manufacturers have made progress, with new models being launched and discussed widely on international social media platforms, indicating a growing interest in AI medical stocks [5] - Securities firms are optimistic about the AI medical sector, with reports highlighting the potential for AI to drive new growth in pharmaceuticals, basic research, diagnosis, and health management [5] - The application of AI in healthcare is entering a rapid commercialization phase, supported by national strategies and market demand, with expectations for significant breakthroughs in the industry [5]

Core Viewpoint - The collaboration between 英矽智能 (Insilico Medicine) and 康哲药业 (Kanghong Pharmaceutical) in AI-driven drug development for central nervous system and autoimmune diseases is expected to enhance innovation and research capabilities in the pharmaceutical industry [1] Group 1: Company Developments - 英矽智能's stock price increased by over 9% to 73.45 HKD, reaching a new high of 74.80 HKD during trading [1] - The company is set to receive up to tens of millions of HKD in research funding for each of the projects under the collaboration agreement with 康哲药业 [1] Group 2: Industry Insights - 大摩 (Morgan Stanley) highlighted 英矽智能 as a leader in the AIDD (AI-Driven Drug Development) field, noting significant progress in both technology validation and application [1] - The execution capability of 英矽智能's chemical models supports a repeatable "1-to-N" innovation creation engine, with potential for further growth as biological model validations become evident [1]

Group 1 - The Hong Kong biotechnology sector continues to strengthen, with notable gains in several companies [1] - Insilico Medicine saw an increase of over 10%, while I-Mab gained more than 7% [1] - Other companies such as Zai Lab, Rongchang Biopharma, and WuXi AppTec also experienced upward movement [1]

消息面上，2月10日，英矽智能与康哲药业宣布在中枢神经系统及自身免疫疾病领域的多个项目上达成 一系列由AI赋能的创新药物研发合作。根据合作协议，双方将结合英矽智能已验证的AI平台与AI赋能 创新药研发能力，以及康哲药业经验丰富的研发团队和对疾病领域的深度认知，共同推进不少于2个研 发项目的合作开发。同时，英矽智能有望就每个项目获得最高达数千万港元的研发费用支持。 大摩此前研报指出，英矽智能是AIDD领域的领先者，在技术验证与应用方面均取得实质性进展。其化 学模型的执行力支撑其可重复的"1-to-N"创新创造引擎；随着生物学模型的人体验证逐步显现，其潜在 上行弹性有望在整个行业进入广泛AIDD采用期时得到进一步释放。 英矽智能(03696)再涨超7%，高见72.55港元创新高。截至发稿，涨7.22%，报72港元，成交额1448.27万 港元。 ...

Core Viewpoint - The stock of Insilico Medicine (03696) has risen over 7%, reaching a new high of 72.55 HKD, driven by a collaboration announcement with Kanghong Pharmaceutical in AI-enabled drug development for central nervous system and autoimmune diseases [1] Group 1: Company Developments - Insilico Medicine and Kanghong Pharmaceutical have entered into a series of collaborative projects focused on AI-driven innovative drug development [1] - The collaboration will leverage Insilico's validated AI platform and drug development capabilities alongside Kanghong's experienced research team and deep understanding of disease areas [1] - Insilico is expected to receive up to tens of millions of HKD in research funding for each project [1] Group 2: Industry Insights - Morgan Stanley's previous report highlights Insilico Medicine as a leader in the AIDD (AI-Driven Drug Development) field, noting substantial progress in both technology validation and application [1] - The execution capability of Insilico's chemical models supports a repeatable "1-to-N" innovation creation engine, indicating strong potential for scalability [1] - As biological model human validation becomes more evident, the potential upside for Insilico is expected to be further released as the industry enters a broader adoption phase of AIDD [1]

Core Viewpoint - Insilico Medicine (03696) has announced a strategic collaboration with Kanghong Pharmaceutical for drug development, focusing on AI-enabled innovative drug research in central nervous system and autoimmune disease areas [1] Group 1: Collaboration Details - The collaboration will leverage Insilico's validated AI platform and innovative drug development capabilities alongside Kanghong's experienced research team and deep understanding of disease areas [1] - The agreement stipulates that both parties will jointly advance at least two research projects [1] Group 2: Financial Aspects - Insilico is expected to receive research funding support of up to several tens of millions of Hong Kong dollars for each project [1]

Core Viewpoint - Insilico Medicine (03696) has announced a strategic collaboration with Kanghong Pharmaceutical for drug development, focusing on AI-powered innovative drug research in central nervous system and autoimmune disease areas [1] Group 1: Collaboration Details - The partnership will leverage Insilico's validated AI platform and drug development capabilities alongside Kanghong's experienced research team and deep understanding of disease areas [1] - The agreement stipulates the joint development of at least two research projects [1] Group 2: Financial Aspects - Insilico is expected to receive research funding support of up to tens of millions of Hong Kong dollars for each project [1]

Group 1 - The core viewpoint of the article is that Insilico Medicine (03696.HK) has entered into a strategic drug development collaboration with Kangji Medical (00867.HK) to leverage AI in innovative drug development for central nervous system and autoimmune diseases [1] - The collaboration will involve at least two research projects that will utilize Insilico's validated AI platform and drug development capabilities, combined with Kangji's experienced research team and deep understanding of disease areas [1] - Insilico is expected to receive research funding support of up to several tens of millions of Hong Kong dollars for each project [1]